---
title: "NeoGenomics Unveils RaDaR ST Liquid Biopsy MRD Assay for Solid Tumor Detection"
description: "NeoGenomics Inc. has announced the presentation of new research at the ISLB Annual Congress 2025, showcasing results from the RaDaR ST Bridging Study, which indicates high concordance between its RaDa"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263579814.md"
published_at: "2025-10-30T16:51:19.000Z"
---

# NeoGenomics Unveils RaDaR ST Liquid Biopsy MRD Assay for Solid Tumor Detection

> NeoGenomics Inc. has announced the presentation of new research at the ISLB Annual Congress 2025, showcasing results from the RaDaR ST Bridging Study, which indicates high concordance between its RaDaR ST and RaDaR 1.0 assays for detecting molecular residual disease in solid tumors. The company will also discuss its NextGen whole genome-based MRD research program and findings from four additional studies. The RaDaR ST assay is expected to launch commercially in Q1 2026.

NeoGenomics Inc. has announced that it will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025. The company will showcase results from the RaDaR ST Bridging Study, which demonstrates high concordance between its RaDaR® ST and RaDaR® 1.0 assays for detecting molecular residual disease (MRD) in solid tumors. Additional presentations will highlight the progress of NeoGenomics’ NextGen whole genome-based MRD research program and findings from four other studies focused on liquid biopsy and comprehensive genomic profiling across various solid tumor types. The expected commercial launch of the RaDaR ST assay is planned for the first quarter of 2026. The results from these studies will be presented at the upcoming ISLB 2025 congress. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251030563337) on October 30, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [NEO.US - Neogenomics](https://longbridge.com/en/quote/NEO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股盘前热门交易：OneConstruction 盘前涨 18.09%；Neogenomics 盘前跌 11.54% | OneConstruction 盘前涨 18.09%；Neogenomics 盘前跌 11.54%；课标科技盘前涨 95.83%；Auddia 盘前涨 83.24%；La Rosa 盘前涨 52.39%。 | [Link](https://longbridge.com/en/news/276230745.md) |
| NeoGenomics 第四季度收入增加，调整后的每股收益超过预期 | NeoGenomics 报告第四季度收入同比增长 11%，主要得益于高价值测试和战略性报销举措。第四季度调整后的每股收益超出分析师预期。公司解决了 RaDaR ST 专利诉讼，并预计 2026 年收入将在 7.93 亿至 8.01 亿美元之 | [Link](https://longbridge.com/en/news/276122102.md) |
| NeoGenomics 推出 PanTracer Pro，以支持及时且知情的实体瘤治疗选择 \| NEO 股票新闻 | NeoGenomics, Inc.推出了 PanTracer Pro，这是一种新的综合测试方法，旨在改善晚期实体肿瘤患者的治疗选择。该解决方案将全面的基因组分析与诊断导向的免疫组化相结合，简化了测试过程并减少了诊断的不确定性。测试结果预计在 | [Link](https://longbridge.com/en/news/275753736.md) |
| Neogenomics 将参与即将举行的投资者会议 \| NEO 股票新闻 | NeoGenomics, Inc.（纳斯达克代码：NEO）将参加即将举行的两个投资者会议：3 月 3 日下午 1:10（东部时间）在波士顿举行的 TD Cowen 第 46 届年度医疗保健会议，以及 3 月 10 日下午 4:20（东部时间 | [Link](https://longbridge.com/en/news/276226329.md) |
| Neogenomics｜8-K：2025 财年 Q4 营收 1.9 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/272266327.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.